[go: up one dir, main page]

Grocott-Mason et al., 1994 - Google Patents

Modulation of left ventricular relaxation in isolated ejecting heart by endogenous nitric oxide

Grocott-Mason et al., 1994

Document ID
12582726193987005670
Author
Grocott-Mason R
Anning P
Evans H
Lewis M
Shah A
Publication year
Publication venue
American Journal of Physiology-Heart and Circulatory Physiology

External Links

Snippet

Nitric oxide (NO) modulates myocardial contractile behavior in several isolated preparations, eg, cardiac myocytes and papillary muscles, via elevation of intracellular guanosine 3', 5'- cyclic monophosphate (cGMP). We have recently reported that the exogenous NO donor …
Continue reading at journals.physiology.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons

Similar Documents

Publication Publication Date Title
Grocott-Mason et al. Modulation of left ventricular relaxation in isolated ejecting heart by endogenous nitric oxide
Grocott-Mason et al. Myocardial relaxant effect of exogenous nitric oxide in isolated ejecting hearts
Paolocci et al. cGMP-independent inotropic effects of nitric oxide and peroxynitrite donors: potential role for nitrosylation
Standl et al. A new look at the heart in diabetes mellitus: from ailing to failing
Remondino et al. Altered expression of proteins of metabolic regulation during remodeling of the left ventricle after myocardial infarction
CA2458798C (en) Method for reducing hypertension and heart failure
Ichinose et al. Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency
Wu et al. Endothelial-dependent vascular effects of insulin and insulin-like growth factor I in the perfused rat mesenteric artery and aortic ring
Krag et al. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome
Penna et al. Postconditioning and intermittent bradykinin induced cardioprotection require cyclooxygenase activation and prostacyclin release during reperfusion
Lasseter et al. The effect of sulfonylurea drugs on rabbit myocardial contractility, canine purkinje fiber automaticity, and adenyl cyclase activity from rabbit and human hearts
AU2002313700A1 (en) Method for reducing hypertension and heart failure
Bucher et al. Role of the l‐arginine‐NO pathway and of cyclic GMP in electrical field‐induced noradrenaline release and vasoconstriction in the rat tail artery
Reil et al. Insights from knock-out models concerning postischemic release of TNFα from isolated mouse hearts
Vanhoutte Endothelium-derived hyperpolarizing factor
Oba et al. Sulfhydryls associated with H2O2-induced channel activation are on luminal side of ryanodine receptors
Morkin et al. Studies on the use of thyroid hormone and a thyroid hormone analogue in the treatment of congestive heart failure
Kamata et al. A comparative study on the rat aorta and mesenteric arterial bed of the possible role of nitric oxide in the desensitization of the vasoconstrictor response to an α1-adrenoceptor agonist
Vidal et al. Dissociation between endothelium-dependent relaxations and increases in cGMP in systemic veins
Donckier et al. Atrial natriuretic factor, cardiac volumes and filling pressures during exercise in congestive heart failure
Masliuko et al. NPY1 receptors participate in the regulation of myocardial contractility in rats
Mertes et al. Consequences of coronary occlusion on changes in regional interstitial myocardial neuropeptide Y and norepinephrine concentrations
Kawada et al. Interstitial norepinephrine level by cardiac microdialysis correlates with ventricular contractility
Symons et al. Knockout of insulin receptors in cardiomyocytes attenuates coronary arterial dysfunction induced by pressure overload
Wang et al. Endothelin-1 promotes vascular structural remodeling during the progression of heart failure: prevention of vascular remodeling using a specific endothelin-converting enzyme inhibitor